ES2130629T3 - Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. - Google Patents

Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.

Info

Publication number
ES2130629T3
ES2130629T3 ES95926642T ES95926642T ES2130629T3 ES 2130629 T3 ES2130629 T3 ES 2130629T3 ES 95926642 T ES95926642 T ES 95926642T ES 95926642 T ES95926642 T ES 95926642T ES 2130629 T3 ES2130629 T3 ES 2130629T3
Authority
ES
Spain
Prior art keywords
proinsulin
diabetes
compounds
type
peptidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926642T
Other languages
English (en)
Inventor
William F Hickey
Ann C Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2130629(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of ES2130629T3 publication Critical patent/ES2130629T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE PEPTIDO DE PROINSULINA, QUE MODULAN LA RESPUESTA INMUNOLOGICA MEDIADA POR CELULAS T, DE SUJETOS DIABETICOS DE TIPO I. LOS COMPUESTOS DE LA INVENCION, SE DERIVAN PREFERIBLEMENTE DE UNA REGION DE LA PROINSULINA, QUE SE EXTIENDE DESDE LA UNION ENTRE LA CADENA B Y EL PEPTIDO C DE LA PROINSULINA. SE DESCRIBEN ASIMISMO, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS DE PEPTIDO DE PROINSULINA. LA RESPUESTA INMUNOLOGICA INDUCIDA POR UN COMPUESTO DE PEPTIDO DE PROINSULINA, SE PUEDE UTILIZAR COMO INDICADOR DE LA DIABETES TIPO I EN UN SUJETO. CONSECUENTEMENTE, LA INVENCION PROPORCIONA ENSAYOS DIAGNOSTICOS PARA LA DIABETES TIPO I, UTILIZANDO DICHOS COMPUESTOS. TAMBIEN SE INCLUYEN METODOS PARA INHIBIR EL DESARROLLO O PROGRESION DE LA DIABETES TIPO I EN UN SUJETO, MEDIANTE LA ADMINISTRACION DE UN COMPUESTO DE PEPTIDO DE PROINSULINA.
ES95926642T 1994-07-08 1995-07-07 Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. Expired - Lifetime ES2130629T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27222094A 1994-07-08 1994-07-08
US47270495A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
ES2130629T3 true ES2130629T3 (es) 1999-07-01

Family

ID=26955374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926642T Expired - Lifetime ES2130629T3 (es) 1994-07-08 1995-07-07 Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.

Country Status (12)

Country Link
US (1) US20030220229A1 (es)
EP (1) EP0788512B1 (es)
JP (1) JPH10505821A (es)
CN (1) CN1157621A (es)
AT (1) ATE178074T1 (es)
AU (1) AU3094795A (es)
CA (1) CA2194548A1 (es)
DE (1) DE69508605T2 (es)
DK (1) DK0788512T3 (es)
ES (1) ES2130629T3 (es)
MX (1) MX9700198A (es)
WO (1) WO1996001846A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637130T2 (de) 1995-02-20 2008-02-21 The Walter And Eliza Hall Institute Of Medical Research, Parkville Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
US7509406B2 (en) * 2004-09-30 2009-03-24 Microsoft Corporation Managing terminal services accounts and sessions for online utilization of a hosted application
ES2331342B1 (es) * 2006-05-22 2010-10-13 Consejo Superior Investg.Cientificas Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
CN103630692B (zh) * 2013-06-02 2015-05-06 马鞍山国声生物技术有限公司 快速检测尿液c肽的胶体金免疫层析试剂盒及其检测方法
JP6560200B2 (ja) * 2013-10-17 2019-08-14 ザ ジェネラル ホスピタル コーポレイション 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
GB2559499A (en) * 2014-02-25 2018-08-08 Orban Tihamer Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
GB2523399B (en) * 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (es) * 1973-07-14 1977-03-26
US4308181A (en) * 1980-12-08 1981-12-29 American Home Products Corporation Polypeptide compositions
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
NL9001083A (nl) * 1990-05-04 1991-12-02 Rijksuniversiteit Beta-cel antigeen.
ATE144326T1 (de) * 1990-08-17 1996-11-15 Univ Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Also Published As

Publication number Publication date
AU3094795A (en) 1996-02-09
US20030220229A1 (en) 2003-11-27
EP0788512B1 (en) 1999-03-24
EP0788512A1 (en) 1997-08-13
DK0788512T3 (da) 1999-10-11
CN1157621A (zh) 1997-08-20
JPH10505821A (ja) 1998-06-09
DE69508605D1 (de) 1999-04-29
ATE178074T1 (de) 1999-04-15
WO1996001846A1 (en) 1996-01-25
DE69508605T2 (de) 1999-07-22
CA2194548A1 (en) 1996-01-25
MX9700198A (es) 1997-04-30

Similar Documents

Publication Publication Date Title
ATE12485T1 (de) Salze der valproinsaeure, ihre herstellung und ihre verwendung.
AR024576A1 (es) Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ES534098A0 (es) Procedimiento para la obtencion de eglinas b o c modificadas
DK524187D0 (da) Aminosyrechelaterede midler til udlevering til specifikke biologiske vaevssteder
IT1195287B (it) Derivato tiazolico,procedimento per la sua preparazione e relative composizioni farmaceutiche
EA200300824A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
WO2003083485A3 (en) Protein for use in hypoxia related conditions
DE3588219D1 (de) T-Zellenrezeptor, spezifisch für Antigenpolypeptide und verwandte Polynukleotide
DK0915974T3 (da) Modificerede tie-2 receptor-ligander
ES2130629T3 (es) Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.
DE69434384D1 (de) Metalkomplexbildner
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
BR9910468A (pt) Composto, complexo radiometálico, preparação para administração em ser humano, kit, usos de um composto e de um complexo radiometálico do composto, e, fragmento de peptìdeo
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
WO1996001846B1 (en) Proinsulin peptide compounds for detecting and treating type i diabetes
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
ATE195147T1 (de) Aminosäuren konjugaten
DK265484A (da) Forbedret fremgangsmaade til fremstilling af steroidestere
DE69929683D1 (de) Antisense modulierung von lfa-3

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 788512

Country of ref document: ES